HWAM
HZNP

Hennion & Walsh Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hennion & Walsh Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-32,622
Closed -$3M – 773
2021
Q1 		$3M Buy
+32,622
New +$2.75M 0.18% 155

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Hennion & Walsh Asset Management's HZNP Position: Q2 2021 in Review

Hennion & Walsh Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 32,622 shares — an estimated $3M sold.

Hennion & Walsh Asset Management first reported a position in HZNP in Q1 2021 and held it in 1 quarter. The position peaked at $3M in Q1 2021. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

  • Hennion & Walsh Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 32,622 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $3M.
  • Hennion & Walsh Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 1 quarter.
  • Hennion & Walsh Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3M in Q1 2021.
  • 526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.